<DOC>
	<DOC>NCT02514603</DOC>
	<brief_summary>The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.</brief_summary>
	<brief_title>A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers</brief_title>
	<detailed_description />
	<criteria>Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed Participant must have diagnosis of cancer that is advanced or metastatic Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding Participant must not have symptomatic central nervous system malignancy or metastasis Participant must not have current hematologic malignancy Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C Participant must not have a serious cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasm metastasis</keyword>
	<keyword>Checkpoint Kinase 1</keyword>
	<keyword>CHK1</keyword>
	<keyword>CHK1 inhibitor</keyword>
</DOC>